Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,384 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03626545 | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy(CANOPY-2) | terminated | Phase 3 | 245 | Novartis PharmaceuticalsINDUSTRY | 26 | Aug 21, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La Roche |
| 21 |
| Jul 28, 2023 |
| clinicaltrials |
| NCT02481830 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer(CheckMate331) | completed | Phase 3 | 569 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 27, 2023 | clinicaltrials |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | terminated | — | 50 | Aristotle University Of ThessalonikiOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection(IMvigor010) | terminated | Phase 3 | 809 | Hoffmann-La RocheINDUSTRY | 24 | Jun 18, 2023 | clinicaltrials |
| NCT05909007 | Post-operative Thoracic Epidural Analgesia and Incidence of Major Complications: a Large Retrospective Dual Center Experi-ence | completed | — | 1,145 | AHEPA University HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT04748744 | Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases | completed | — | 400 | University Hospital of PatrasOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02303444 | An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors(RIFTOS MKI) | completed | — | 667 | BayerINDUSTRY | 19 | Jun 8, 2023 | clinicaltrials |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma(LIGHTHOUSE) | terminated | Phase 3 | 54 | Oncopeptides ABINDUSTRY | 11 | Jun 8, 2023 | clinicaltrials |
| NCT01734928 | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(OPTIMISMM) | completed | Phase 3 | 559 | CelgeneINDUSTRY | 22 | Jun 6, 2023 | clinicaltrials |
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | completed | Phase 2 | 150 | AmgenINDUSTRY | 9 | Jun 5, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05378854 | Training Data Collection & AI Development(LC_SSP) | completed | N/A | 27 | Aristotle University Of ThessalonikiOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)(VENICE I) | completed | Phase 3 | 258 | AbbVieINDUSTRY | 21 | Apr 10, 2023 | clinicaltrials |
| NCT05758948 | Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer | unknown | — | 101 | Hellenic Cooperative Oncology GroupOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04866290 | HepaSphere™ Microspheres Prospective Registry(mCRC) | completed | — | 105 | Merit Medical Systems, Inc.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT02726581 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma(CheckMate 602) | completed | Phase 3 | 170 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 27, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT04724031 | Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer | unknown | — | 150 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function(BRIDGE) | terminated | Phase 2 | 35 | Oncopeptides ABINDUSTRY | 3 | Mar 10, 2023 | clinicaltrials |
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04365790 | Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma | unknown | — | 500 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04403984 | Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes | unknown | — | 750 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05127382 | Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer | unknown | — | 40 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT04752865 | Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04983628 | Molecular Profiling in Prostate Cancer(ProProstate) | unknown | — | 250 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT04586751 | The Impact of Pecs Blocks on Postmastectomy Pain Syndrome | completed | N/A | 64 | Aretaieion University HospitalOTHER | 2 | Feb 8, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | terminated | Phase 2 / Phase 3 | 1 | Nektar TherapeuticsINDUSTRY | 4 | Jan 12, 2023 | clinicaltrials |
| NCT05675176 | Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer | completed | — | 100 | National and Kapodistrian University of AthensOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04442334 | The European NAFLD Registry | recruiting | — | 10,000 | Newcastle UniversityOTHER | 12 | Jan 6, 2023 | clinicaltrials |
| NCT05537922 | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | recruiting | — | 2,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 4 | Jan 6, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | completed | Phase 2 | 122 | Millennium Pharmaceuticals, Inc.INDUSTRY | 18 | Dec 20, 2022 | clinicaltrials |
| NCT03091127 | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | completed | — | 705 | AmgenINDUSTRY | 11 | Dec 12, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials